Cargando…
Mocetinostat activates Krüppel-like factor 4 and protects against tissue destruction and inflammation in osteoarthritis
Osteoarthritis (OA) is the most common joint disorder, and disease-modifying OA drugs (DMOADs) represent a major need in OA management. Krüppel-like factor 4 (KLF4) is a central transcription factor upregulating regenerative and protective functions in joint tissues. This study was aimed to identify...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10544226/ https://www.ncbi.nlm.nih.gov/pubmed/37681413 http://dx.doi.org/10.1172/jci.insight.170513 |
_version_ | 1785114459498348544 |
---|---|
author | Kawata, Manabu McClatchy, Daniel B. Diedrich, Jolene K. Olmer, Merissa Johnson, Kristen A. Yates, John R. Lotz, Martin K. |
author_facet | Kawata, Manabu McClatchy, Daniel B. Diedrich, Jolene K. Olmer, Merissa Johnson, Kristen A. Yates, John R. Lotz, Martin K. |
author_sort | Kawata, Manabu |
collection | PubMed |
description | Osteoarthritis (OA) is the most common joint disorder, and disease-modifying OA drugs (DMOADs) represent a major need in OA management. Krüppel-like factor 4 (KLF4) is a central transcription factor upregulating regenerative and protective functions in joint tissues. This study was aimed to identify small molecules activating KLF4 expression and to determine functions and mechanisms of the hit compounds. High-throughput screening (HTS) with 11,948 clinical-stage compounds was performed using a reporter cell line detecting endogenous KLF4 activation. Eighteen compounds were identified through the HTS and confirmed in a secondary screen. After testing in SW1353 chondrosarcoma cells and human chondrocytes, mocetinostat — a class I selective histone deacetylase (HDAC) inhibitor — had the best profile of biological activities. Mocetinostat upregulated cartilage signature genes in human chondrocytes, meniscal cells, and BM-derived mesenchymal stem cells, and it downregulated hypertrophic, inflammatory, and catabolic genes in those cells and synoviocytes. I.p. administration of mocetinostat into mice reduced severity of OA-associated changes and improved pain behaviors. Global gene expression and proteomics analyses revealed that regenerative and protective effects of mocetinostat were dependent on peroxisome proliferator-activated receptor γ coactivator 1-α. These findings show therapeutic and protective activities of mocetinostat against OA, qualifying it as a candidate to be used as a DMOAD. |
format | Online Article Text |
id | pubmed-10544226 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Society for Clinical Investigation |
record_format | MEDLINE/PubMed |
spelling | pubmed-105442262023-10-03 Mocetinostat activates Krüppel-like factor 4 and protects against tissue destruction and inflammation in osteoarthritis Kawata, Manabu McClatchy, Daniel B. Diedrich, Jolene K. Olmer, Merissa Johnson, Kristen A. Yates, John R. Lotz, Martin K. JCI Insight Research Article Osteoarthritis (OA) is the most common joint disorder, and disease-modifying OA drugs (DMOADs) represent a major need in OA management. Krüppel-like factor 4 (KLF4) is a central transcription factor upregulating regenerative and protective functions in joint tissues. This study was aimed to identify small molecules activating KLF4 expression and to determine functions and mechanisms of the hit compounds. High-throughput screening (HTS) with 11,948 clinical-stage compounds was performed using a reporter cell line detecting endogenous KLF4 activation. Eighteen compounds were identified through the HTS and confirmed in a secondary screen. After testing in SW1353 chondrosarcoma cells and human chondrocytes, mocetinostat — a class I selective histone deacetylase (HDAC) inhibitor — had the best profile of biological activities. Mocetinostat upregulated cartilage signature genes in human chondrocytes, meniscal cells, and BM-derived mesenchymal stem cells, and it downregulated hypertrophic, inflammatory, and catabolic genes in those cells and synoviocytes. I.p. administration of mocetinostat into mice reduced severity of OA-associated changes and improved pain behaviors. Global gene expression and proteomics analyses revealed that regenerative and protective effects of mocetinostat were dependent on peroxisome proliferator-activated receptor γ coactivator 1-α. These findings show therapeutic and protective activities of mocetinostat against OA, qualifying it as a candidate to be used as a DMOAD. American Society for Clinical Investigation 2023-09-08 /pmc/articles/PMC10544226/ /pubmed/37681413 http://dx.doi.org/10.1172/jci.insight.170513 Text en © 2023 Kawata et al. https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Article Kawata, Manabu McClatchy, Daniel B. Diedrich, Jolene K. Olmer, Merissa Johnson, Kristen A. Yates, John R. Lotz, Martin K. Mocetinostat activates Krüppel-like factor 4 and protects against tissue destruction and inflammation in osteoarthritis |
title | Mocetinostat activates Krüppel-like factor 4 and protects against tissue destruction and inflammation in osteoarthritis |
title_full | Mocetinostat activates Krüppel-like factor 4 and protects against tissue destruction and inflammation in osteoarthritis |
title_fullStr | Mocetinostat activates Krüppel-like factor 4 and protects against tissue destruction and inflammation in osteoarthritis |
title_full_unstemmed | Mocetinostat activates Krüppel-like factor 4 and protects against tissue destruction and inflammation in osteoarthritis |
title_short | Mocetinostat activates Krüppel-like factor 4 and protects against tissue destruction and inflammation in osteoarthritis |
title_sort | mocetinostat activates krüppel-like factor 4 and protects against tissue destruction and inflammation in osteoarthritis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10544226/ https://www.ncbi.nlm.nih.gov/pubmed/37681413 http://dx.doi.org/10.1172/jci.insight.170513 |
work_keys_str_mv | AT kawatamanabu mocetinostatactivateskruppellikefactor4andprotectsagainsttissuedestructionandinflammationinosteoarthritis AT mcclatchydanielb mocetinostatactivateskruppellikefactor4andprotectsagainsttissuedestructionandinflammationinosteoarthritis AT diedrichjolenek mocetinostatactivateskruppellikefactor4andprotectsagainsttissuedestructionandinflammationinosteoarthritis AT olmermerissa mocetinostatactivateskruppellikefactor4andprotectsagainsttissuedestructionandinflammationinosteoarthritis AT johnsonkristena mocetinostatactivateskruppellikefactor4andprotectsagainsttissuedestructionandinflammationinosteoarthritis AT yatesjohnr mocetinostatactivateskruppellikefactor4andprotectsagainsttissuedestructionandinflammationinosteoarthritis AT lotzmartink mocetinostatactivateskruppellikefactor4andprotectsagainsttissuedestructionandinflammationinosteoarthritis |